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With an insidious manifestation and chronic evolution,ntroduction
t is estimated that the human T lymphotropic virus type
 (HTLV-1) infects approximately 20 million people world-
ide. Associated diseases, however, manifest only in 5–10%
f infected individuals.1 Studies have shown that HTLV-1 is
ndemic in Southern Japan, the Caribbean, South America,
elanesian islands, Papua New Guinea, the Middle East and
entral and Southern Africa. In Brazil, HTLV-1 infection is con-
idered a public health concern as the country ﬁgures among
he endemic areas in the world with prevalence rates from 1%
o 5%.1Since the discovery of HTLV-1 in 1979, it has been clearly
ssociated with hematologic disorders, speciﬁcally with adult
-cell leukemia/lymphoma (ATL), an aggressive neoplasm
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eserved.with poor prognosis.1 Although ATL has clinical forms with
different manifestations, it is generally characterized as a
clonal proliferation of CD4+ T cells containing randomly dis-
tributed HTLV-1 proviral integration sites. The onset of the
disease usually occurs 20–30 years after viral infection and
is primarily associated with vertical transmission, mainly
through breastfeeding by a seropositive woman.1
Apart from ATL, other diseases have been consistently
linked to HTLV-1 infection over the years. Tropical spastic
paraparesis/HTLV-1-associated myelopathy (TSP/HAM) more
frequently affects women, with onset ranging from years
to decades after infection, at an average age of 40 years.1), Avenida Alfredo Balena, 190, 2◦ andar, sala 243, 30130-100, Belo
om.br (S.M. Rezende).
HAM/TSP takes years to progress from the onset of symp-
toms, such as weakness and spasticity of one or both legs
and minor sensory changes, to wheelchair conﬁnement and
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bowel/bladder incontinence.1 Other diseases such as uveitis,
infective dermatitis, pulmonary and rheumatic disorders such
as rheumatoid arthritis and Sjögren’s syndrome, as well as
other autoimmune conditions such as bronco-alveolar pneu-
monitis, autoimmune thyroiditis and endemic polymyositis,
have also been associated with HTLV-1 infection.1,2 In addi-
tion, in the last two decades, HTLV-1 has been reported
in association with other blood diseases, such as acute
myeloid leukemia,3 idiopathic thrombocytopenic purpura4
and myelodysplastic syndrome.5
Case  report
A 27-year-old woman was referred for a hematology consulta-
tion to investigate pancytopenia. At admission, she had spas-
tic paraparesis, and bowel and bladder dysfunction, clinical
signs consistent with the initial presentation of HAM/TSP. Her
symptoms started as a progressive weakness of the legs when
she was 22 years old. The patient was born in a known endemic
area for HTLV-1 infection, located in the Northern Region of
Minas Gerais State, Brazil. Although there was no history of
blood transfusion, she reported that she was breastfed by a
wet nurse. HTLV-1 testing was performed and the positive
enzyme immunoassay results were conﬁrmed by western blot.
No alterations were found in cerebrospinal ﬂuid analysis or a
computed tomography (CT) scan of the lumbosacral spine. At
admission, she presented with pancytopenia that had been
investigated in another hospital in 1996 by bone marrow aspi-
rate and biopsy; at that time, no abnormalities were found.
These results could not be checked due to the lack of material.
Later in the same year, the patient was hospitalized for
another investigation of the pancytopenia and metrorrha-
gia. During her hospitalization, the patient received 600 mL  of
packed red cells and daily platelet transfusions. The absolute
neutrophil count ranged from 1.310 × 109/L to 2.060 × 109/L
(reference range [RR] = 4.0 × 109/L to 11.0 × 109/L); platelet
count varied from 3.74 × 109/L to 64.00 × 109/L (RR = 150 × 109/L
to 450 × 109/L) and hemoglobin levels were between 6.0 g/dL
and 8.4 g/dL (RR = 12 g/dL to 14 g/dL). The reticulocyte count
was 3.7% (RR = 0.5% to 1.5%) with the absolute red cell count
of 2.35 × 103/L. Abdominal ultrasound revealed liver at 4 cm
below the lower edge of the right costal margin and the spleen
was classiﬁed as Boyd grade III.
Several tests were carried out to investigate the cause of
the pancytopenia, including leishmaniasis, HIV, hepatitis B
and C, syphilis and antinuclear antibody test, all with neg-
ative results. Tests for vitamin B12, folate, iron serum levels
and other routine tests were also performed, with results
within normal reference ranges. A bone marrow aspirate and
biopsy showed increased cellularity, abnormal distribution of
erythropoiesis, atypical megakaryocytes, immature granulo-
cytes and evidence of reactive marrow ﬁbrosis. Marrow iron
stores were normal. The metrorrhagia was controlled with the
administration of combined oral contraceptives.
Throughout 11 years, a non-progressive pancytopenia was
the only persistent sign of a hematological disorder. A sig-
niﬁcant hepatosplenomegaly was noticed and conﬁrmed by
imaging in 2002. The liver and spleen were no longer pal-
pable in the patient’s ﬁrst consultation in our outpatients’r. 2 0 1 6;3 8(1):75–78
clinic in 2009. An abdominal CT scan, performed in 2009,
revealed mild splenomegaly with no other abdominal abnor-
malities. Petechiae were present in her consultation, mainly
in the oral cavity. Platelet counts were consistently below
40.0 × 109/L and absolute neutrophil counts varied from
1.5 × 109/L to 2.0 × 109/L, with relative lymphocytosis (58% to
65%). A discrete normocytic normochromic anemia could be
observed in most of the blood tests, with hemoglobin varying
from 10.5 g/dL to 12 g/dL. In addition, the patient presented
increased lactate dehydrogenase (LDH) levels, with values
ranging from 902 U/L to 1020 U/L (RR: 313–618 U/L). Hepatic
enzymes and calcium levels were unremarkable. A high dose
of prednisone (60 mg  per day) was prescribed to increase
platelet counts but was stopped as it was not effective.
The patient was tested and proved to be negative for: (i) the
V617F mutation of the Janus kinase 2 (JAK2) gene, (ii) W515L
and W515K mutations of the MPL  gene and (iii) the BCR-ABL
fusion gene. Furthermore, sequencing of the coding region of
exon 12 of JAK2 and exon 9 of the calreticulin (CALR) gene was
performed by capillary electrophoresis but no mutations were
found. She had a normal karyotype by G banding analysis.
The antinuclear antibody test was positive for anti-cytoplasm
in 1:360–1:640 dilution (RR: <1:80) and 2-microglobulin was
slightly increased (3.47 g/mL; RR: <2.4 g/mL). Bone mar-
row aspiration and biopsy were repeated in 2013 (Figure 1).
The biopsy sample was stained using hematoxylin and
eosin, periodic acid-Schiff (PAS), giemsa, silver impregnation
(Gordon-Sweet), Masson’s trichrome, and Perls. Immunostain-
ing was performed for CD2, CD3, CD4, CD5, CD8, CD20, CD30,
CD34, CD56 and FOXP3. The lymphocytes reacted with variable
intensity for CD2, CD3, CD4, CD5 and CD8 but were negative
for CD56 and FOXP3. The reaction with CD4 was more  intense
than with CD8. CD34 positive blasts were not identiﬁed.
The reaction with CD61 highlighted the intense proliferation
of atypical/small and medium sized megakaryocytes, with
hypolobulated nuclei and rare naked nuclei (Figure 1A, B and
F). The remaining parenchyma showed intense subversion of
architecture due to severe grade 3 ﬁbrosis (reticulin and colla-
gen) and due to the neovascular formation and osteosclerosis
(Figure 1C–E). There was scanty representation of the myeloid
and erythrocytic series. At the present, the patient is taking
2 mg  clonazepam, 10 mg Baclofen, and 5 mg  prednisone daily.
Discussion
HTLV-1 infection has long been described in association with
hematological and auto-immune disorders.1,2 In this case,
ATL was ruled out due to the absence of typical ATL ‘ﬂower
cells’ characterized by intermediate to large pleomorphic
cells, sometimes with hyperlobulated nuclei CD4+/CD8− and
the absence of bone marrow inﬁltration. Of the myelopro-
liferative neoplasms (MPN), chronic myeloid leukemia and
polycythemia vera were also ruled out due to the absence of
the BCR-ABL fusion gene and the JAK2 V617F mutation, respec-
tively, and lack of remaining clinical and laboratory criteria
used to diagnose both conditions, including the absence of
the W515L and W515K mutations of the MPL  gene.
The presence of atypical megakaryocytes, bone marrow
ﬁbrosis, increased LDH, and pancytopenia suggested the
rev bras hematol hemoter. 2 0 1 6;3 8(1):75–78 77
Figure 1 – Bone marrow biopsy. (A and B) Bone marrow biopsy stained using hematoxylin and eosin showing clusters of
abnormal megakaryocytes (arrow). (C and D) Bone marrow biopsy stained using Gordon Sweet stain showing a marked
increase in coarse reticulin ﬁbers (arrow). (E) Perivascular collagen ﬁbrosis stained using Masson’s trichrome (arrow). (F)
Immunostaining for CD61 with megakaryocyte hyperplasia (arrow).
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aiagnosis of myeloﬁbrosis. Myeloﬁbrosis, characterized by
hronic and persistent pancytopenia associated with bone
arrow ﬁbrosis and proliferation of megakaryocytes, is one of
he most common types of MPN.  It can be primary or develop
s an end-stage bone marrow failure, secondary to other MPN.
yeloﬁbrosis can also be present as a reaction of the bone
arrow against other neoplasms or inﬂammatory processes,
nd can emerge as an autoimmune phenomenon.6,7 Classi-
al ﬁndings of primary myeloﬁbrosis are hepatosplenomegaly,
eardrop erythrocytes and leukoerythroblastosis in the periph-
ral blood, which were not present in this patient. Moreover,
he benign, non-progressive course of the disease disfavored
he diagnosis of primary myeloﬁbrosis as the median sur-
ival of patients with this condition is about 69 months.8 The
linical picture and laboratory tests suggest the diagnosis of
utoimmune myeloﬁbrosis (AIMF).
AIMF is an under-recognized cause of marrow ﬁbrosis, and
as been deﬁned using the following criteria: (1) Grade 3 or
 reticulin ﬁbrosis of the bone marrow; (2) lack of clustered
r atypical megakaryocytes; (3) lack of myeloid or erythroid
ysplasia, eosinophilia, or basophilia; (4) lymphocyte inﬁltra-
ion of the bone marrow; (5) lack of osteosclerosis; (6) absent
r mild splenomegaly; (7) presence of autoantibodies; and (8)
bsence of a disorder known to cause myeloﬁbrosis.6 A recent
tudy reported that mild atypias including occasional clus-
ered, left-shifted, small, and hypolobated megakaryocytes,
an be observed in AIMF.7AIMF is classiﬁed as primary or secondary, the latter
amed when associated with autoimmune disorders. Dis-
ases such as systemic lupus erythematous (SLE), scleroderma
nd Sjögren’s syndrome are the main disorders describedin association with secondary AIMF.6,7 AIMF has also been
described in association with HIV infection9 but not with HTLV
infection. The differentiation between AIMF and the MPN-
related myeloﬁbrosis is imperative once these disorders have
different management and prognoses. AIMF tends to respond
well to steroids and/or other immunosuppressive agents and
has a better prognosis.
An additional unusual aspect of this case is the rare over-
lap of HTLV-1-related diseases: HAM/TSP and a hematological
disorder. ATL and HAM/TSP seem to differ in their route
of transmission (ATL being mainly via breast-feeding, and
HAM/TSP via blood transfusion), pathogenesis and immuno-
logical response. After infection, both cellular and humoral
immune responses are formed against HTLV. The humoral
reaction contributes as delayed protection by producing anti-
bodies against viral proteins, including Tax. However, recently,
Tax-antibodies have been associated with the development
of HAM/TSP, suggesting an autoimmune component to the
disease. This antibody could also be associated with AIMF. Fur-
thermore, HAM/TSP apparently relates to patients with high
proviral loads, which is supposedly determined by host fac-
tors such as polymorphisms in the major histocompatibility
complex class I (MHC-I) molecules and its inﬂuence on antigen
presentation to CD8+ T-cells.
In conclusion, this is the case of a young woman with HTLV-
1 infection and HAM/TSP, who evolved with pancytopenia and
bone marrow ﬁbrosis. To our knowledge, except for a short
report by Engels,10 who does not provide detailed information,
this is the ﬁrst report of AIMF associated with HTLV-1 infec-
tion. This case report strengthens the described association
between HTLV-1 and autoimmune/hematological disorders.
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